

Organizers' contacts:

Lui G. Forni, PhD, MB, JFICMI
University of Surrey
Guildford, UK
Tel +44 1483 402724
Email: luiformi@nhs.net

Mitra K. Nadim, MD, FASN
Keck School of Medicine of USC
Los Angeles, CA 90089
Tel +1 323 442 6894
Email: nadim@usc.edu

Alexander Zarbock, MD, PhD
University Hospital Münster
Münster, Germany
Tel: +49 251 83-44017
Email: zarbock@uni-muenster.de

Claudio Ronco, MD
Email: cronco@goldnet.it

This ADQI Conference is made possible by the generous contribution of unrestricted educational grants of several companies including:

Baxter	BioMérieux SA
Cytosorbents	Sphingotec
OCD	Jafron
Exthera	Spectral

European Organization Support
New Progress Service srl
dr.ssa Anna Saccardo +39 3401607312
admin@npsevents.it nps@cgn.legalmail.it

Acute Disease Quality Initiative

ADQI was started in response to concerns about the quality of care delivered to patients with **Acute Kidney Injury (AKI)** based on published data demonstrating that AKI is associated with an unacceptably high mortality, and there is a wide practice variation in its diagnosis and management worldwide.

In order to address these issues, ADQI has adopted an evidence-based methodology to develop consensus-based recommendations for managing patients with AKI. The key goal of the ADQI process is to ultimately provide evidence-based guidelines for the management of AKI. Consequently, we have initiated a series of conferences under the auspices of the **Acute Disease Quality Initiative**.

ADQI aims at establishing an evidence-based appraisal and set of consensus recommendations to standardize care and direct further research. The results of previous consensus conferences are available on-line at www.adqi.net.


ADQI 28 Sepsis Associated Acute Kidney Injury (SA-AKI)

The ADQI 28 conference is focused on "Sepsis Associated Acute Kidney Injury". Sepsis remains the most important cause of AKI in the critically ill and it is associated with short term mortality, SA-AKI is also linked to the development of CKD, ESKD, and long-term increased risk of death. Furthermore, approximately 20% of patients with SA-AKI require RRT. Despite this, treatment recommendations for SA-AKI lack sophistication championing source control, avoidance of secondary kidney injury, and optimization of systemic hemodynamics. Participants are experts in the field who will review existing evidence and will make recommendations for current practice and for future research on the treatment of SA-AKI.

Lui G. Forni, Mitra Nadim, Alex Zarbock and Claudio Ronco

Co-Organizers of the 2022 28th ADQI Conference include:

- The Surrey Peri-Operative, Anaesthesia & Critical Care Collaborative Research Group
- Keck School of Medicine, University of Southern California
- Westphalian Wilhelm's University of Münster
- The International Renal Research Institute of Vicenza (IRRIV)



Acute Disease Quality Initiative

**A process towards developing
consensus and recommendations for
management of sepsis-associated AKI**

www.ADQI.net

**Hotel Villa Michelangelo,
Arcugnano di Vicenza, Italy
17th to 19th June 2022**

CONFERENCE STRUCTURE

The 28th ADQI conference will utilize the same format and methodology employed previously: an iterative process of debate and consensus building using modified Delphi principles (www.adqi.net). Recommendations will be evidence-based and consensus driven.

Prior to the conference, participants will be organized into small groups and will systematically gather the evidence in the literature on each topic. Each sub-group will be responsible for defining the specific questions that will be addressed for each topic and presenting key evidence to the group.

The 5 groups will have prepared their topic ahead of the meeting, and will develop their manuscript and presentations during the course of the meeting and immediately after.

The specific objectives for this conference are:

- ❖ *To develop a series of consensus statements on Sepsis Associated AKI. This methodology includes:*
 - Pre-conference evidence abstraction
 - Identification of key questions, clarify points of consensus and controversy
 - Assessment of the available evidence and identify areas where evidence is lacking
 - Plenary sessions to present evidence appraisal
 - Iterative refining of recommendations
 - Design a research agenda at several levels – conceptual, programmatic & individual study designs
 - Draft summary statements for each topic
 - External peer review of statements
- ❖ *The primary focus of this meeting will be to provide recommendations for clinical practice and future research. Specific topics assigned to groups will include:*
 - **Group 1: Epidemiology**
 - **Group 2: Pathophysiology & Novel Targets.**
 - **Group 3: Fluids & Resuscitation Strategies**
 - **Group 4: Biomarkers for Diagnosis and Treatment**
 - **Group 5: Extra-Corporeal and Novel Therapies**

PROGRAM

Friday 17th June

Morning: Arrival of delegates and welcome coffee

10:00	Welcome and Introductions (Organizers) Methodology and “Ground Rules” (Forni)
10:15	Plenary 1: Group Chairs (15 min/group) Updates on pre-conference progress
11:30	Breakout Session 1
13:00	Lunch
13:30	Break out session 1 (continued)
14:30	Plenary 2 (definition of Questions)
16:30	Adjourn
17:30	Bus departure for social event

Saturday 18th June

Breakfast available from 7 am

8:00	Breakout Session 2
10:30	Coffee break
11:00	Plenary 3 (Draft statements Identification of controversies)
13:00	Lunch
13:30	Breakout session 3
15:30	Draft consensus statements
16:00	Adjourn
17:00	Bus departure for social event

Sunday 19th June

Breakfast available from 7 am

8:30	Plenary 4: Group Chairs Final statements
11:00	Closing comments and next steps
	Farewell party
	Departures

FACULTY

Organizers/Chairs

Lui Forni (UK)
Mitra K. Nadim (USA)
Alexander Zarbock (Germany)
Claudio Ronco (Italy)

ADQI Council Members

Claudio Ronco (Italy)
Rinaldo Bellomo (Australia)
Ravindra Mehta (USA)
Marlies Ostermann (UK)

ADQI 28 Faculty and Groups:

Group 1 Epidemiology

Chair: Neesh Pannu (Canada) – Samira Bell (UK)
Members: Marlies Ostermann (UK), Zaccaria Ricci (Italy), Xose Fernandez-Perez (Spain), John Prowle (UK)

Group 2 Pathophysiology & Novel Targets

Chair: Peter Pickkers (Netherlands) – Hernando Gomez (USA)
Members: Jean L Vincent (Belgium), Steve Opal (USA), Vincenzo Cantaluppi (Italy), Sarah Faubel (USA)

Group 3 Fluids & Resuscitation Strategies

Chair: Michael Joannidis (Austria) – Melanie Meersch (Germany)
Members: Rinaldo Bellomo (Australia), Rajit Basu (USA)
Yvelynne Kelly (Ireland), Ravindra Mehta (USA)

Group 4 Biomarkers for Diagnosis and Treatment

Chair: Jay Koyner (USA) – Kianoush Kashani (USA)
Members: Emily See (Australia), Patrick Murray (Ireland), Sean Bagshaw (Canada), Sandra L Kane-Gill (USA)

Group 5 Extra-Corporeal and Novel Therapies

Chair: Thomas Rimmelé (France), Thiago Reis (Brazil)
Members: Danielle Soranno (USA), Gianluca Villa (Italy), Ashita Tolwani (USA), Faeq Husain-Syed (Germany), Silvia De Rosa (Italy)